Tasly Pharmaceutical Posts Higher 2025 Profit Despite Revenue Dip and Reliance on One-Off Gains

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.

Tasly Pharmaceutical Group Co., Ltd., a consolidated subsidiary of China Resources Pharmaceutical Group, reported unaudited preliminary results for 2025 showing a slight 3.1% decline in total operating revenue to RMB 8.24 billion but notable improvements in profitability metrics. Operating profit and total profit rose about 25% year-on-year, while net profit attributable to shareholders increased 15.7% and basic earnings per share climbed to RMB 0.74, alongside a higher weighted average return on net assets and modest growth in total assets and net assets per share. However, net profit excluding extraordinary gains or losses dropped 24.1%, indicating that one-off items played a significant role in earnings, a dynamic that may affect quality-of-earnings assessments for investors and has implications for China Resources Pharmaceutical’s consolidated financial performance given Tasly’s status as a key subsidiary.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. is a major Chinese healthcare conglomerate with operations spanning pharmaceutical manufacturing, distribution and retail. Through its non-wholly-owned subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., it holds about 28% of Shanghai-listed Tasly Pharmaceutical Group Co., Ltd., which is consolidated as a subsidiary and contributes to the Group’s earnings and asset base.

Average Trading Volume: 12,510,133

Technical Sentiment Signal: Sell

Current Market Cap: HK$28.15B

For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.